title: Positive effects of short-term growth hormone treatment on lean body mass and BMC after a hip fracture: a double-blind placebo-controlled pilot study in 20 patients.
abstract: BACKGROUND
  A catabolic state develops after a hip fracture, with loss of muscle and bone tissue. Growth hormone (GH) treatment has been shown to exert anabolic effects during other catabolic states. We investigated whether GH given postoperatively to elderly hip fracture patients could increase serum insulin-like growth factor-I (IGF-I) and reduce the loss of lean body mass and bone mineral content (BMC) without considerable side effects.
  
  
  METHODS
  We randomized 20 patients operated on for a hip fracture to a double-blind placebo-controlled 4-week study with daily subcutaneous injections of GH or placebo. The patients were followed for another 2 months after termination of GH treatment.
  
  
  RESULTS
  Serum IGF-I and the IGF-I binding protein 1 (IGFBP-1) were measured by specific radioimmunoassay (RIA) technique. BMC and lean body mass were assessed by dual-energy X-ray absorptiometry and quantitative computed tomography. Serum IGF-I increased significantly during GH treatment, which also preserved lean body mass and BMC without serious adverse events.
authors.affiliation: Division of Orthopaedics, Danderyd Hospital, SE-182 88 Stockholm, Sweden. margareta.hedstrom@hs.se
authors.forename: Margareta
authors.initials: M
authors.lastname: Hedström
authors.forename: Maria
authors.initials: M
authors.lastname: Sääf
authors.forename: Eva
authors.initials: E
authors.lastname: Brosjö
authors.forename: Carolin
authors.initials: C
authors.lastname: Hurtig
authors.forename: Kerstin
authors.initials: K
authors.lastname: Sjöberg
authors.forename: Ann
authors.initials: A
authors.lastname: Wesslau
authors.forename: Nils
authors.initials: N
authors.lastname: Dalén
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D015992:Body Mass Index; D015519:Bone Density / Q000187:drug effects*; D004311:Double-Blind Method; D005260:Female; D013006:Growth Hormone / Q000008:administration & dosage*; D006620:Hip Fractures / Q000097:blood* / Q000150:complications* / Q000378:metabolism; D006801:Humans; D018970:Insulin-Like Growth Factor Binding Protein 1 / Q000097:blood*; D007334:Insulin-Like Growth Factor I / Q000032:analysis*; D008297:Male; D010865:Pilot Projects; D013997:Time Factors
chemical_list: D018970:Insulin-Like Growth Factor Binding Protein 1; D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone